COVID-19 Results Briefing

The United States of America

July 14, 2021

This document contains summary information on the latest projections from the IHME model on COVID-19 in the United States of America. The model was run on July 13, 2021, with data through July 12, 2021.

Despite vaccination rates in the population reaching nearly to 49% and 38% of the population having been previously infected, COVID-19 transmission is increasing in 38 states. The reversal in the epidemic is reflected in rising daily reported cases and hospitalizations at the national level. The increase is driven by the spread of the more transmissible Delta variant, which also appears to demonstrate immune escape from previous infection. Studies show that the mRNA vaccines and other vaccines have some reduction in vaccine efficacy against the Delta variant. The widespread shift from declining transmission to increasing transmission is also greatly facilitated by the reduction in mask wearing to less than one quarter of the population and general increases in mobility and social interaction. Multiple countries including the United Kingdom, Greece, Spain, Cyprus, Indonesia, Thailand, Vietnam, and multiple countries in sub-Saharan Africa are reporting rapid surges in case numbers due to the Delta variant. These explosive surges have not yet appeared in the US. Our models suggest steady increases through to November 1 in infections, reported cases, and daily deaths. We do not yet forecast the exponential surges seen in other countries. The lower risk of very rapid increases is likely due to higher rates of prior infection and higher rates of vaccination with the more effective mRNA vaccines. More rapid increases are certainly possible given the demonstrated transmission potential of the Delta variant. Close monitoring of breakthrough infections in the vaccinated will be important to get a more precise assessment of immune escape, which will influence the speed of spread. Clearly COVID-19 is not over in the US, and the spread of the Delta variant means a summer surge in many states followed by a likely larger surge in the late fall and winter. The main strategies to deal with the pandemic remain maximizing vaccination rates with mRNA vaccines by targeting the vaccine hesitant. Hesitancy data are now available at the Zip code level to help in identifying communities where outreach may have the greatest impact. When and if surges accelerate, reimposition of mask mandates may be required as the logical next step.

Current situation

- Daily reported cases in the last week (through July 12) increased to 18,000 per day on average compared to 15,100 the week before (Figure 1).
- Reported deaths due to COVID-19 in the last week decreased to 200 per day on average compared to 230 the week before (Figure 2).
- Excess deaths due to COVID-19 in the last week decreased to 320 per day on average compared to 370 the week before (Figure 2). This makes COVID-19 the number 6 cause of death in the US this week (Table 1). Estimated excess daily deaths due to COVID-19 were 1.5 times larger than the reported number of deaths.
• No locations had daily reported COVID-19 death rates greater than 4 per million (Figure 3).

• No states had daily death rates greater than 4 per million (Figure 3).

• We estimated that 38% of people in the US have been infected as of July 12 (Figure 5).

• Effective R, computed using cases, hospitalizations, and deaths, is greater than 1 in 38 states (Figure 6). Transmission is increasing on average more in Southern states than in the Midwest or Northeast.

• The infection-detection rate in the US was close to 18% on July 12 (Figure 7).

• Based on the GISAID and various national databases, combined with our variant spread model, we estimate the current prevalence of variants of concern (Figure 8). We estimate that B.1.351 is circulating in seven states, that B.1.617 is circulating in 50 states and the District of Columbia, and that P.1 is circulating in 25 states.

Trends in drivers of transmission

• Very few mandates are in place across US states. Hawaii is the only state with a mask mandate. Any type of gathering restriction is only in place in Kansas, Kentucky, North Dakota, and Rhode Island (Table 2).

• Mobility last week was 11% lower than the pre-COVID-19 baseline (Figure 10). Mobility was near baseline (within 10%) in 37 states. Mobility was lower than 30% of baseline in no locations.

• As of July 12, in the COVID-19 Trends and Impact Survey, 24% of people self-report that they always wore a mask when leaving their home (Figure 12).

• There were 324 diagnostic tests per 100,000 people on July 12 (Figure 14).

• In US 72.8% of people say they would accept or would probably accept a vaccine for COVID-19. This is up by 0.3 percentage points from last week. The fraction of the adult population who are open to receiving a COVID-19 vaccine ranges from 49% in Mississippi to 90% in Hawaii (Figure 18).

• In our current reference scenario, we expect that 182.0 million people will be vaccinated by November 1 (Figure 19). Taking into account how many people will complete the full schedule and the vaccine efficacy of Pfizer, Moderna, and Johnson & Johnson vaccines, we estimate that 62% of adults will have effective vaccine-derived immunity by November 1.
Projections

• In our **reference scenario**, which represents what we think is most likely to happen, our model projects 653,000 cumulative reported deaths due to COVID-19 on November 1. This represents 50,000 additional deaths from July 12 to November 1. Daily reported deaths will rise to 580 by October 1, 2021, and then level off. (Figure 20).

• Under our **reference scenario**, our model projects 1,016,000 cumulative excess deaths due to COVID-19 on November 1 (Figure 20).

• If **universal mask coverage (95%)** were attained in the next week, our model projects 36,000 fewer cumulative reported deaths compared to the reference scenario on November 1.

• Under our **worse scenario**, our model projects 663,000 cumulative reported deaths on November 1, an additional 9,900 deaths compared to our reference scenario. Daily reported deaths in the worse scenario will rise to 730 on November 1, 2021 (Figure 20).

• Daily infections in the reference scenario will rise to 256,000 on November 1, 2021 (Figure 25). Daily infections in the worse scenario will rise to 342,000 on November 1, 2021 (Figure 25).

• Figure 22 compares our reference scenario forecasts to other publicly archived models. The MIT (Delphi) model projects continued declines in daily deaths. The other models, including the CDC ensemble, suggest rising daily deaths. In October, across the model the range is from 600 to 800.

• At some point from July through November 1, 12 states will have high or extreme stress on hospital beds (Figure 23). At some point from July through November 1, 14 states will have high or extreme stress on intensive care unit (ICU) capacity (Figure 24).
Model updates

No model updates.
Figure 1. Reported daily COVID-19 cases

Table 1. Ranking of excess deaths due to COVID-19 among the leading causes of mortality this week, assuming uniform deaths of non-COVID causes throughout the year

<table>
<thead>
<tr>
<th>Cause name</th>
<th>Weekly deaths</th>
<th>Ranking</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischemic heart disease</td>
<td>10,724</td>
<td>1</td>
</tr>
<tr>
<td>Tracheal, bronchus, and lung cancer</td>
<td>3,965</td>
<td>2</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>3,766</td>
<td>3</td>
</tr>
<tr>
<td>Stroke</td>
<td>3,643</td>
<td>4</td>
</tr>
<tr>
<td>Alzheimer’s disease and other dementias</td>
<td>2,768</td>
<td>5</td>
</tr>
<tr>
<td>COVID-19</td>
<td>2,273</td>
<td>6</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>2,057</td>
<td>7</td>
</tr>
<tr>
<td>Colon and rectum cancer</td>
<td>1,616</td>
<td>8</td>
</tr>
<tr>
<td>Lower respiratory infections</td>
<td>1,575</td>
<td>9</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>1,495</td>
<td>10</td>
</tr>
</tbody>
</table>
Figure 2. Smoothed trend estimate of reported daily COVID-19 deaths (blue) and excess daily deaths due to COVID-19 (orange).
Figure 3. Daily COVID-19 death rate per 1 million on July 12, 2021

A. Daily reported COVID-19 death rate per 1 million

B. Daily excess COVID-19 death rate per 1 million
**Figure 4.** Cumulative COVID-19 deaths per 100,000 on July 12, 2021

A. Reported cumulative COVID-19 deaths per 100,000

B. Excess cumulative COVID-19 deaths per 100,000
Figure 5. Estimated percent of the population infected with COVID-19 on July 12, 2021.

Figure 6. Mean effective R on July 1, 2021. The estimate of effective R is based on the combined analysis of deaths, case reporting, and hospitalizations where available. Current reported cases reflect infections 11-13 days prior, so estimates of effective R can only be made for the recent past. Effective R less than 1 means that transmission should decline, all other things being held the same.
Figure 7. Percent of COVID-19 infections detected. This is estimated as the ratio of reported daily COVID-19 cases to estimated daily COVID-19 infections based on the SEIR disease transmission model. Due to measurement errors in cases and testing rates, the infection-detection rate can exceed 100% at particular points in time.
Figure 8. Estimated percent of circulating SARS-CoV-2 for primary variant families on July 12, 2021.

A. Estimated percent B.1.1.7 variant

B. Estimated percent B.1.351 variant
C. Estimated percent B.1.617 variant

D. Estimated percent P.1 variant
Figure 9. Infection-fatality ratio on July 12, 2021
Critical drivers

Table 2. Current mandate implementation
**Figure 10.** Trend in mobility as measured through smartphone app use compared to January 2020 baseline.

**Figure 11.** Mobility level as measured through smartphone app use compared to January 2020 baseline (percent) on July 12, 2021.
Figure 12. Trend in the proportion of the population reporting always wearing a mask when leaving home

Figure 13. Proportion of the population reporting always wearing a mask when leaving home on July 12, 2021
Figure 14. Trend in COVID-19 diagnostic tests per 100,000 people

Figure 15. COVID-19 diagnostic tests per 100,000 people on July 12, 2021
Figure 16. Increase in the risk of death due to pneumonia on February 1 compared to August 1
Table 3. Estimates of vaccine efficacy for specific vaccines used in the model at preventing disease and infection. The SEIR model uses variant-specific estimates of vaccine efficacy at preventing symptomatic disease and at preventing infection. We use data from clinical trials directly, where available, and make estimates otherwise. More information can be found on our website.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Efficacy at preventing disease: D614G &amp; B.1.1.7</th>
<th>Efficacy at preventing infection: D614G &amp; B.1.1.7</th>
<th>Efficacy at preventing disease: B.1.351, B.1.617, &amp; P.1</th>
<th>Efficacy at preventing infection: B.1.351, B.1.617, &amp; P.1</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca</td>
<td>74%</td>
<td>52%</td>
<td>53%</td>
<td>47%</td>
</tr>
<tr>
<td>CoronaVac</td>
<td>50%</td>
<td>44%</td>
<td>40%</td>
<td>35%</td>
</tr>
<tr>
<td>Covaxin</td>
<td>78%</td>
<td>69%</td>
<td>62%</td>
<td>55%</td>
</tr>
<tr>
<td>Janssen</td>
<td>72%</td>
<td>72%</td>
<td>64%</td>
<td>56%</td>
</tr>
<tr>
<td>Moderna</td>
<td>94%</td>
<td>89%</td>
<td>83%</td>
<td>79%</td>
</tr>
<tr>
<td>Novavax</td>
<td>89%</td>
<td>79%</td>
<td>73%</td>
<td>64%</td>
</tr>
<tr>
<td>Pfizer/BioNTech</td>
<td>91%</td>
<td>86%</td>
<td>81%</td>
<td>77%</td>
</tr>
<tr>
<td>Sinopharm</td>
<td>73%</td>
<td>65%</td>
<td>47%</td>
<td>41%</td>
</tr>
<tr>
<td>Sputnik-V</td>
<td>92%</td>
<td>81%</td>
<td>73%</td>
<td>65%</td>
</tr>
<tr>
<td>Tianjin</td>
<td>66%</td>
<td>58%</td>
<td>53%</td>
<td>47%</td>
</tr>
<tr>
<td>CanSino</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other vaccines</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other vaccines (mRNA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

covid19.healthdata.org 18 Institute for Health Metrics and Evaluation
**Figure 17.** Trend in the estimated proportion of the adult (18+) population that have been vaccinated or would probably or definitely receive the COVID-19 vaccine if available.

**Figure 18.** This figure shows the estimated proportion of the adult (18+) population that has been vaccinated or would probably or definitely receive the COVID-19 vaccine if available.
**Figure 19.** Number of people who receive any vaccine and those who are effectively vaccinated and protected against disease, accounting for efficacy, loss to follow up for two-dose vaccines, partial immunity after one dose, and immunity after two doses.
Projections and scenarios

We produce three scenarios when projecting COVID-19. The reference scenario is our forecast of what we think is most likely to happen:

- Vaccines are distributed at the expected pace.
- Governments adapt their response by re-imposing social distancing mandates for 6 weeks whenever daily deaths reach 8 per million, unless a location has already spent at least 7 of the last 14 days with daily deaths above this rate and not yet re-imposed social distancing mandates. In this case, the scenario assumes that mandates are re-imposed when daily deaths reach 15 per million.
- Variants B.1.1.7 (first identified in the UK), B.1.351 (first identified in South Africa), and P1 (first identified in Brazil) continue to spread from locations with (a) more than 5 sequenced variants, and (b) reports of community transmission, to adjacent locations following the speed of variant scale-up observed in the regions of the United Kingdom.
- In one-quarter of those vaccinated, mobility increases toward pre-COVID-19 levels.

The worse scenario modifies the reference scenario assumptions in three ways:

- First, it assumes that variants B.1.351 or P.1 begin to spread within three weeks in adjacent locations that do not already have B.1.351 or P.1 community transmission.
- Second, it assumes that all those vaccinated increase their mobility toward pre-COVID-19 levels.
- Third, it assumes that among those vaccinated, mask use starts to decline exponentially one month after completed vaccination.

The universal masks scenario makes all the same assumptions as the reference scenario but also assumes 95% of the population wear masks in public in every location.
Figure 20. Daily COVID-19 deaths until November 01, 2021 for three scenarios

A. Reported daily COVID-19 death per 100,000

B. Excess daily COVID-19 deaths per 100,000
Figure 21. Daily COVID-19 infections until November 01, 2021 for three scenarios
Figure 22. Comparison of reference model projections with other COVID modeling groups. For this comparison, we are including projections of daily COVID-19 deaths from other modeling groups when available: Delphi from the Massachusetts Institute of Technology (Delphi), Imperial College London (Imperial), The Los Alamos National Laboratory (LANL), the SI-KJalpha model from the University of Southern California (SIKJalpha), and the CDC Ensemble Model (CDC). Daily deaths from other modeling groups are smoothed to remove inconsistencies with rounding. Regional values are aggregates from available locations in that region.
Figure 23. The estimated inpatient hospital usage is shown over time. The percent of hospital beds occupied by COVID-19 patients is color-coded based on observed quantiles of the maximum proportion of beds occupied by COVID-19 patients. Less than 5% is considered low stress, 5-9% is considered moderate stress, 10-19% is considered high stress, and 20% or greater is considered extreme stress.
Figure 24. The estimated intensive care unit (ICU) usage is shown over time. The percent of ICU beds occupied by COVID-19 patients is color-coded based on observed quantiles of the maximum proportion of ICU beds occupied by COVID-19 patients. Less than 10% is considered low stress, 10-29% is considered moderate stress, 30-59% is considered high stress, and 60% or greater is considered extreme stress.
More information

Data sources:
Mask use and vaccine confidence data are from the The Delphi Group at Carnegie Mellon University and University of Maryland COVID-19 Trends and Impact Surveys, in partnership with Facebook. Mask use data are also from Premise, the Kaiser Family Foundation, and the YouGov COVID-19 Behaviour Tracker survey.

Genetic sequence and metadata are primarily from the GISAID Initiative. Further details available on the COVID-19 model FAQ page.

A note of thanks:
We wish to warmly acknowledge the support of these and others who have made our COVID-19 estimation efforts possible.

More information:
For all COVID-19 resources at IHME, visit http://www.healthdata.org/covid.